BRPI0608012A2 - método de tratamento de cáncer, método de aumento de atividade de célula nk, método de aumento de resposta ou atividade th1 inata, método de tratamento de uma disfunção mediada por th2, método de tratamento de uma doença imune, usos de uma molécula antagonista e uso de uma molécula agonista - Google Patents

método de tratamento de cáncer, método de aumento de atividade de célula nk, método de aumento de resposta ou atividade th1 inata, método de tratamento de uma disfunção mediada por th2, método de tratamento de uma doença imune, usos de uma molécula antagonista e uso de uma molécula agonista

Info

Publication number
BRPI0608012A2
BRPI0608012A2 BRPI0608012-0A BRPI0608012A BRPI0608012A2 BR PI0608012 A2 BRPI0608012 A2 BR PI0608012A2 BR PI0608012 A BRPI0608012 A BR PI0608012A BR PI0608012 A2 BRPI0608012 A2 BR PI0608012A2
Authority
BR
Brazil
Prior art keywords
treatment
activity increase
molecule
response
innate
Prior art date
Application number
BRPI0608012-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Avi J Ashkenazi
Heather Maecker
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36953868&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0608012(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BRPI0608012A2 publication Critical patent/BRPI0608012A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0608012-0A 2005-03-07 2006-03-02 método de tratamento de cáncer, método de aumento de atividade de célula nk, método de aumento de resposta ou atividade th1 inata, método de tratamento de uma disfunção mediada por th2, método de tratamento de uma doença imune, usos de uma molécula antagonista e uso de uma molécula agonista BRPI0608012A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65933905P 2005-03-07 2005-03-07
PCT/US2006/007547 WO2006096487A2 (en) 2005-03-07 2006-03-02 Methods and compositions for modulating tweak and fn14 activity

Publications (1)

Publication Number Publication Date
BRPI0608012A2 true BRPI0608012A2 (pt) 2009-11-03

Family

ID=36953868

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0608012-0A BRPI0608012A2 (pt) 2005-03-07 2006-03-02 método de tratamento de cáncer, método de aumento de atividade de célula nk, método de aumento de resposta ou atividade th1 inata, método de tratamento de uma disfunção mediada por th2, método de tratamento de uma doença imune, usos de uma molécula antagonista e uso de uma molécula agonista

Country Status (12)

Country Link
US (2) US20080286271A1 (cg-RX-API-DMAC7.html)
EP (1) EP1853312B1 (cg-RX-API-DMAC7.html)
JP (2) JP2008531746A (cg-RX-API-DMAC7.html)
KR (3) KR20130089271A (cg-RX-API-DMAC7.html)
CN (2) CN101171035A (cg-RX-API-DMAC7.html)
AU (1) AU2006220825A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0608012A2 (cg-RX-API-DMAC7.html)
CA (1) CA2597485A1 (cg-RX-API-DMAC7.html)
IL (1) IL185180A0 (cg-RX-API-DMAC7.html)
RU (1) RU2007137060A (cg-RX-API-DMAC7.html)
WO (1) WO2006096487A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200707489B (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0105044A3 (en) 1999-01-15 2004-07-28 Biogen Inc Cambridge Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
US7208151B2 (en) 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
AU2003224950B2 (en) 2002-04-09 2006-09-14 Biogen Ma Inc. Methods for treating tweak-related conditions
DK2332408T3 (da) 2005-02-17 2013-12-02 Biogen Idec Inc Behandling af neurologiske sygdomme
WO2006088890A2 (en) * 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating stroke
KR20130089271A (ko) * 2005-03-07 2013-08-09 제넨테크, 인크. Ｔｗｅａｋ 및 ｆｎ14 활성을 조절하는 방법 및 조성물
WO2006122187A2 (en) * 2005-05-10 2006-11-16 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
WO2006130429A2 (en) * 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Treatment of cancer
NZ583636A (en) 2005-05-27 2011-12-22 Biogen Idec Inc Tweak binding antibodies
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
US20100284933A1 (en) * 2006-10-16 2010-11-11 Biogen Idec Ma Inc. Biomarkers of Multiple Sclerosis
MX2010001378A (es) * 2007-08-03 2010-06-02 Facet Biotech Corp Uso terapeutico de anticuerpos del receptor anti-tweak.
US8093006B2 (en) 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof
US20120055055A1 (en) * 2010-09-02 2012-03-08 Illumin8 Outdoor Media, LLC Systems and Method for Outdoor Media Signage
WO2012045671A1 (en) * 2010-10-05 2012-04-12 F. Hoffmann-La Roche Ag Antibodies against human tweak and uses thereof
JP5832559B2 (ja) * 2011-03-10 2015-12-16 オメロス コーポレーション ｅｘｖｉｖｏにおける加速された抗体進化による抗ＦＮ１４モノクローナル抗体の生成
JP2016000003A (ja) * 2013-04-19 2016-01-07 アステラス製薬株式会社 新規抗ヒトｔｗｅａｋ抗体
CN105779576B (zh) * 2014-12-25 2025-01-17 中国人民解放军第四军医大学 人tnfrsf12a基因的用途及其相关药物
US10994017B2 (en) 2016-12-02 2021-05-04 Avelas Biosciences, Inc. Nerve labeling compositions and uses thereof
MY204672A (en) 2018-10-31 2024-09-09 Astellas Pharma Inc Anti-human fn14 antibody

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998035061A2 (en) * 1997-02-12 1998-08-13 Abbott Laboratories Member of the tnf family useful for treatment and diagnosis of disease
HUP0105044A3 (en) * 1999-01-15 2004-07-28 Biogen Inc Cambridge Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
EP1626058B1 (en) * 1999-03-08 2007-10-31 Genentech, Inc. Compositions and methods for the diagnosis of tumour
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
EP2298334A3 (en) * 1999-12-20 2012-04-04 Immunex Corporation Tweak receptor
US6727225B2 (en) 1999-12-20 2004-04-27 Immunex Corporation TWEAK receptor
CA2422095A1 (en) * 2000-09-14 2002-03-21 Biogen, Inc. Tweak receptor agonists as anti-angiogenic agents
AU2002220265A1 (en) * 2000-11-03 2002-05-15 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
US7393531B2 (en) * 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
CA2587018A1 (en) * 2004-11-08 2006-05-18 University Of Maryland, Baltimore Tweak as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
KR20130089271A (ko) * 2005-03-07 2013-08-09 제넨테크, 인크. Ｔｗｅａｋ 및 ｆｎ14 활성을 조절하는 방법 및 조성물

Also Published As

Publication number Publication date
US20120269808A1 (en) 2012-10-25
RU2007137060A (ru) 2009-04-20
EP1853312A2 (en) 2007-11-14
ZA200707489B (en) 2008-12-31
WO2006096487A3 (en) 2007-09-13
JP2014111605A (ja) 2014-06-19
WO2006096487A2 (en) 2006-09-14
AU2006220825A2 (en) 2006-09-14
KR20070108537A (ko) 2007-11-12
CN101171035A (zh) 2008-04-30
KR20150031459A (ko) 2015-03-24
CA2597485A1 (en) 2006-09-14
AU2006220825A1 (en) 2006-09-14
IL185180A0 (en) 2008-12-29
JP2008531746A (ja) 2008-08-14
EP1853312B1 (en) 2014-12-10
KR20130089271A (ko) 2013-08-09
US20080286271A1 (en) 2008-11-20
CN102225200A (zh) 2011-10-26

Similar Documents

Publication Publication Date Title
BRPI0608012A2 (pt) método de tratamento de cáncer, método de aumento de atividade de célula nk, método de aumento de resposta ou atividade th1 inata, método de tratamento de uma disfunção mediada por th2, método de tratamento de uma doença imune, usos de uma molécula antagonista e uso de uma molécula agonista
CR11042A (es) Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
EA201001256A1 (ru) Производные диазаспиро[5.5]ундекана в качестве антагонистов мускариновых рецепторов и агонистов бета-адренорецепторов для применения в лечении легочных расстройств
CL2008001826A1 (es) Metodos y composicion para el tratamiento de enfermedades alergicas anticuerpo anti-receptor de linfopoyetina estromal timica humana (tslp) o porcion de enlace de antigeno del mismo; polinucleotido que lo codifica; celula huesped; composicion farmaceutica que lo comprende; y su uso para tratar una enfermedad o trastorno inflamatorio en un sujeto
EA201071291A2 (ru) Nmda рецепторные антагонисты для лечения нейропсихиатрических расстройств
EA201270467A1 (ru) Полициклические соединения в качестве антагонистов рецепторов лизофосфатидной кислоты
BR112014018728A8 (pt) Compostos de purinonas como inibidores de quinase
NI200700260A (es) Antagonistas de npy, preparación y usos.
CR11849A (es) Agonistas mezclados, basados en gip para el tratamiento de trastornos metabólicos y obesidad
BR112015021888A2 (pt) inibidores de dna-ik
CL2018001089A1 (es) Sales de valbenazina y polimorfos de las mismas.
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
EA200602062A1 (ru) Амидосоединения и их применение в качестве фармацевтических средств
UY33616A (es) Compuestos con estructura de imidazotriazinona
ECSP067021A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
MX2019005232A (es) Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
EA201101709A1 (ru) Полициклические антагонисты рецепторов лизофосфатидной кислоты
CO6361994A2 (es) Antagonistas del receptor de orexina de isonicotinamida
CL2011002056A1 (es) Compuestos derivados del acido {7-([1,2,3]triazol-1-il)-6,7,8,9-tetrahidropirido[1,2-a]indol-10-il}-acetico, antagonista del receptor crth2; composicion farmaceutica que lo comprende; utiles ene l tratamiento del asma, alergias, cancer entre otras.
UY32968A (es) Compuestos heterocíclicos fusionados como moduladores del receptor de orexina
TW200732347A (en) VEGF analogs and methods of use
CL2014003110A1 (es) Anticuerpo anti-fcrn; secuencias que lo codifican; vector; célula huésped; proceso de producción; composición farmacéutica que lo comprende; uso para el tratamiento de enfermedad autoinmune; y ensayo para probar la capacidad de un anticuerpo para bloquear la actividad de fcrn humano.
DOP2012000246A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]